Here are five things to know:
1. Bayer’s pharmaceutical division head, Dieter Weinand, will leave the company and join Sanofi’s leadership team as an executive vice president.
2. At Sanofi, Mr. Weinand will oversee a primary care unit that will comprise diabetes and cardiovascular treatments. He will report to Sanofi’s CEO Olivier Brandicourt and be based in New Jersey.
3. Stefan Oelrich, head of diabetes at Sanofi, will replace Mr. Weinand as the head of Bayer’s pharmaceutical division. He will take the helm in November.
4. The job swap, for Bayer, comes as the drugmaker considers job cuts and outsourcing as part of a review of its drug research and development operations
5. Bayer said Mr. Weinand, who was based in Germany, decided to leave for family reasons, according to the report.
More articles on pharmacy:
Hospitals mark up drugs by 479%: 6 report findings
6 latest drug, medical device recalls
400% price hike for generic drug a ‘moral requirement,’ Missouri pharma CEO says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
